
Article 1 
The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.
Article 2 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 20 September 2018.
For the Commission
The President
Jean-Claude JUNCKER
ANNEX

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

((1)) in the sixth column, expiration of approval, of row 316, Cycloxydim, the date is replaced by ‘31 May 2023’;
((2)) in the sixth column, expiration of approval, of row 317, 6-Benzyladenine, the date is replaced by ‘31 May 2024’;
((3)) in the sixth column, expiration of approval, of row 322, Hymexazol, the date is replaced by ‘31 May 2023’;
((4)) in the sixth column, expiration of approval, of row 323, Dodine, the date is replaced by ‘31 May 2024’;
((5)) in the sixth column, expiration of approval, of row 326, Indolylbutyric acid, the date is replaced by ‘31 May 2023’;
((6)) in the sixth column, expiration of approval, of row 328, Tau-fluvalinate, the date is replaced by ‘31 May 2024’;
((7)) in the sixth column, expiration of approval, of row 329, Clethodim, the date is replaced by ‘31 May 2023’;
((8)) in the sixth column, expiration of approval, of row 330, Bupirimate, the date is replaced by ‘31 May 2024’;
((9)) in the sixth column, expiration of approval, of row 333, 1-decanol, the date is replaced by ‘31 May 2024’;
((10)) in the sixth column, expiration of approval, of row 334, Isoxaben, the date is replaced by ‘31 May 2024’;
((11)) in the sixth column, expiration of approval, of row 335, Fluometuron, the date is replaced by ‘31 May 2024’;
((12)) in the sixth column, expiration of approval, of row 337, Carboxin, the date is replaced by ‘31 May 2023’;
((13)) in the sixth column, expiration of approval, of row 339, Dazomet, the date is replaced by ‘31 May 2023’;
((14)) in the sixth column, expiration of approval, of row 340, Metaldehyde, the date is replaced by ‘31 May 2023’;
((15)) in the sixth column, expiration of approval, of row 341, Sintofen, the date is replaced by ‘31 May 2024’;
((16)) in the sixth column, expiration of approval, of row 342, Fenazaquin, the date is replaced by ‘31 May 2023’;
((17)) in the sixth column, expiration of approval, of row 343, Azadirachtin, the date is replaced by ‘31 May 2024’;
((18)) in the sixth column, expiration of approval, of row 344, Diclofop, the date is replaced by ‘31 May 2023’;
((19)) in the sixth column, expiration of approval, of row 345, Lime sulphur, the date is replaced by ‘31 May 2024’;
((20)) in the sixth column, expiration of approval, of row 346, Aluminium sulfate, the date is replaced by ‘31 May 2024’;
((21)) in the sixth column, expiration of approval, of row 348, Paclobutrazol, the date is replaced by ‘31 May 2023’;
((22)) in the sixth column, expiration of approval, of row 349, Pencycuron, the date is replaced by ‘31 May 2024’;
((23)) in the sixth column, expiration of approval, of row 350, Tebufenozide, the date is replaced by ‘31 May 2024’;
((24)) in the sixth column, expiration of approval, of row 351, Dithianon, the date is replaced by ‘31 May 2024’;
((25)) in the sixth column, expiration of approval, of row 352, Hexythiazox, the date is replaced by ‘31 May 2024’;
((26)) in the sixth column, expiration of approval, of row 353, Flutriafol, the date is replaced by ‘31 May 2024’.
